Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

It affects approximately 100,000 children and adults in the US. The MEK1 and MEK2 inhibitor showed that it was able to reduce NF1-PN lesions in the 114-patient phase 2b ReNeu trial, with an ...

Coming after Ogsiveo at SprongWorks is Gomekli (mirdametinib), an oral small molecule designed to inhibit MEK1 and MEK2 proteins, which has been submitted for FDA approval as a treatment for ...

MYC amplification and protein expression as prognostic markers in pediatric and young adult osteosarcoma. This is an ASCO Meeting Abstract from the 2025 ASCO Annual Meeting I. This abstract does not ...

Interim safety and efficacy data of [212Pb]VMT01 in MC1R expressing melanoma. Zanzalintinib (zanza) + nivolumab (nivo) ± relatlimab (rela) in patients (pts) with advanced solid tumors: Results from ...

At close: May 30 at 4:00:00 p.m. EDT ...